Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Biotechnology

Healthcare
$3.50 +0.57%

+$0.03 today

Market cap
$555.14M
Beta
0.80
P/E (TTM)
-8.2
EPS (TTM)
-$0.54
52W Low $1.34High $5.15

Volume 2.94M

Average 1.40M

ACRS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Aclaris Therapeutics, Inc.NASDAQ: ACRS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $15.66M rose 35.2% year over year, behind the +60.6% change in trailing-twelve-month research & development. Sequentially, it fell 5.6% from the prior quarter. Over 3 fiscal years it compounded at -12.2% a year.

Context

  • Research & development amounted to 672.7% of revenue in FY2025, up 493.3 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +35.2% toward the trailing-twelve-month pace of +60.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.66M-5.6% QoQ
Last fiscal yearDec 2025
$52.65M+56.7% YoY
LTMMar 2026
$56.72M+60.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.2%——
1 year+56.7%——
3-year CAGR-12.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
52.65M USD
Year-over-year change
+56.7%
4-year CAGR
+4.7%

Research & Development vs competitors

How ACRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +60.6% is the 2nd highest of 10, against a peer median of -8.4%.
  • Research & development amounts to 677.9% of revenue for ACRS, versus a peer median of 4348.4%.
ACRS Competitors
Research & Development for ACRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$346.63M USD-8.7%+56.3%4685.4%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$220.82M USD+62.1%+69.0%—
TRAXFirst Tracks Biotherapeutics IncFY2025$139.61M USD-8.4%——
ANABAnaptysBio, Inc.LTM Mar 2026$128.65M USD-23.4%+15.3%55.4%
IMUXImmunic, Inc.LTM Mar 2026$86.08M USD+3.9%+4.8%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M USD+60.6%-12.2%677.9%
ATTOAttovia Therapeutics, Inc.FY2025$54.15M USD+59.9%—4011.3%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€39.31M EUR+49.4%——
IFRXInflaRx N.V.LTM Mar 2026€22.87M EUR-34.8%-11.8%77989.1%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$20.65M USD-58.3%-18.4%—
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ACRS) —-8.4%+10.0%4348.4%

Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.76M29.75M31.25M18.72M7.83M
Cost of Revenue4.71M11.96M18.08M2.79M2.09M
Gross Profit2.05M17.79M13.17M15.93M5.74M
Gross Margin30.3%59.8%42.1%85.1%73.3%
Research & Development43.81M77.81M98.38M33.59M52.65M
Selling, General & Admin23.62M25.13M31.1M22.2M21.97M
Operating Expenses91.77M107.65M110.53M157.86M82.11M
Depreciation & Amortization923K797K863K807K454K
EBITDA(64.46M)(84.36M)(115.45M)(51.72M)(64.47M)
EBITDA Margin-953.4%-283.5%-369.5%-276.3%-823.8%
Operating Income(89.72M)(89.85M)(97.36M)(141.93M)(76.38M)
Operating Margin-1327.1%-302.0%-311.6%-758.2%-975.9%
Interest Income0007.95M7.64M
Interest Expense00000
Other Income / Expenses(1.14M)2.95M8.51M9.87M11.45M
Income Before Tax(90.87M)(86.91M)(88.85M)(132.07M)(64.92M)
Pre-Tax Margin-1344.0%-292.1%-284.3%-705.5%-829.6%
Income Tax Expense00(367K)00
Net Income(90.87M)(86.91M)(88.48M)(132.07M)(64.92M)
Net Margin-1344.0%-292.1%-283.1%-705.5%-829.6%
EPS (Basic)(1.60)(1.33)(1.27)(1.71)(0.53)
EPS (Diluted)(1.60)(1.33)(1.27)(1.71)(0.53)
Weighted Avg Shares56.73M65.21M69.81M77.3M122.66M
Weighted Avg Shares (Diluted)56.73M65.21M69.81M77.3M122.66M

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.